Status
Conditions
Treatments
About
The purposes of this research are to investigate (1) if schizophrenia patients and at-risk individuals present bradykinesia and dyskinesia and (2) if tDCS improves motor performance in schizophrenia patients and at-risk individuals. The first hypothesis is that both schizophrenia patients and at-risk individuals show bradykinesia and dyskinesia, and the motor symptoms are more severe in the former than the latter. The second hypothesis is that tDCS improves motor performance in schizophrenia patients and at-risk cases.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for schizophrenia patients:
No Exclusion Criteria.
Inclusion Criteria for at-risk individuals:
No Exclusion Criteria.
Inclusion Criteria for healthy controls:
No Exclusion Criteria.
Primary purpose
Allocation
Interventional model
Masking
120 participants in 8 patient groups
Loading...
Central trial contact
Shu-Mei Wang, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal